Previous 10 | Next 10 |
Fycompa® is the 16 th Captisol-enabled™ product approved worldwide Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour a...
2024-02-21 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-16 11:10:43 ET More on iShares Russell 2000 ETF: IWM: Technical Analysis Says You Should Buy Small Caps IWM: Supply-Side Disinflation Benefits Small Caps The Most Small-Cap ETFs: Performance, Fundamentals, And Rankings For 102 Funds Investors retract ...
Expansion Deepens Ligand’s Commercial, Clinical and Investment Expertise Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen Reeves, M.D., to Senior Vice Presid...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Tuesday, February 27, 2024, and will hold a conference call at 8:30 a.m. Eastern Time that same day to dis...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that effective February 1, 2024, Ligand’s Board of Directors approved the grant of non-qualified stock option awards to purchase an aggregate of 93,700 shares of its common stock, 32,750 restricted stock units (“RSUs...
2024-01-23 07:08:06 ET More on Genmab, Johnson & Johnson, etc. Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off? Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition Genmab: 3 Trends To Track For A Strong...
2024-01-20 08:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Partnership expands Henlius’ portfolio with license of exclusive China rights to develop, manufacture and commercialize lasofoxifene; Sermonix retains all other global rights Henlius to facilitate clinical development for the initiated Phase 3 MRCT (ELAINE-3) of lasofoxifene in the...
2024-01-05 17:02:45 ET More on Ligand Pharmaceuticals Ligand Pharmaceuticals: A Complicated Tale Ligand Pharmaceuticals Inc. (LGND) Q3 2023 Earnings Call Transcript Ligand Pharmaceuticals Non-GAAP EPS of $1.02 beats by $0.40, revenue of $32.87M beats by $5.65M ...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
CAPVAXIVE is the sixth FDA-approved product to utilize the Pfenex Expression Technology® platform Ligand is entitled to a royalty on worldwide net sales of CAPVAXIVE Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as...
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference cal...